GCP
RPTX

GSA Capital Partners’s Repare Therapeutics RPTX Stock Holding History

GSA Capital Partners’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,862
Closed -$24K – 2032
2025
Q3 		$24K Buy
+13,862
New +$22.2K ﹤0.01% 1584
2025
Q1 		– Sell
-117,296
Closed -$154K – 2016
2024
Q4 		$154K Sell
117,296
-123,226
-51% -$367K 0.01% 1461
2024
Q3 		$827K Sell
240,522
-59,132
-20% -$195K 0.06% 589
2024
Q2 		$989K Buy
299,654
+173,446
+137% +$619K 0.07% 509
2024
Q1 		$594K Sell
126,208
-18,242
-13% -$117K 0.05% 777
2023
Q4 		$1.05M Buy
144,450
+121,309
+524% +$679K 0.09% 362
2023
Q3 		$280K Buy
+23,141
New +$239K 0.02% 1119

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

GSA Capital Partners's RPTX Position: Q4 2025 in Review

GSA Capital Partners sold out of Repare Therapeutics (RPTX) in Q4 2025, closing a stake of 13,862 shares — an estimated $24K sold.

GSA Capital Partners first reported a position in RPTX in Q3 2023 and held it in 7 quarters. The position peaked at $1.05M in Q4 2023. 46 funds tracked by Wall St. Rank hold RPTX as of Q4 2025.

  • GSA Capital Partners reported no remaining Repare Therapeutics position as of Q4 2025 after selling out during the quarter.
  • GSA Capital Partners sold 13,862 Repare Therapeutics shares in Q4 2025, an estimated $24K.
  • GSA Capital Partners first reported a position in Repare Therapeutics in Q3 2023 and held it in 7 quarters.
  • GSA Capital Partners's Repare Therapeutics position peaked at $1.05M in Q4 2023.
  • 46 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.